MAIA — Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 · 2019 · Multiple Myeloma

Design

Open-label randomized trial of daratumumab plus lenalidomide-dexamethasone (D-Rd) versus Rd until progression.

Population

Newly diagnosed multiple myeloma patients ineligible for autologous stem-cell transplant.

Primary Endpoint

progression-free survival (PFS)

Key Result

Long-term analysis (~7.5 yr): median OS 90.3 vs 64.1 mo (HR 0.67); median PFS 61.9 vs 34.4 mo (HR 0.55).

Guideline Impact

NCCN category 1 / preferred for transplant-ineligible newly diagnosed myeloma